No Data
Two Sessions Time | National People's Congress Representative, Lu Qingguo from Chenguang Biotech Group: Improve the quality standards of Chinese Patent Medicine, regulate the centralized procurement model for Traditional Chinese Medicine, and optimize the
① Lu Qingguo, Director of Chenguang Biotech Group and a representative of the National People's Congress, focused on several recommendations at this year's Two Sessions, including optimizing the procurement mechanism for Traditional Chinese Medicine, enhancing the quality standards for Chinese Patent Medicine, and standardizing the Traditional Chinese Medicine granule industry; ② In addition to recommendations related to the Traditional Chinese Medicine industry, Lu Qingguo prepared several suggestions on rural social retirement insurance, rural medical insurance, and increasing support for companies sanctioned by the United States.
Shareholder Yuanjia Medical has completed its shareholding in ST Meye (600671.SH), with a cumulative increase of 1.1141 million shares.
The announcement from ST Yao Medicine (600671.SH) states that the shareholder Yuanjia Medical has completed the implementation of its shareholding plan, and from 202...
ST Miao Pharmaceutical (600671.SH): Yuanjia Medical has cumulatively increased its shareholding by 0.65% in the company.
Gelonghui reported on February 17 that Special Treat Moxibustion (600671.SH) announced that from August 24, 2024, to February 17, 2025, Yuanjia Medical has cumulatively increased its shareholding of the company by 739,900 shares through centralized bidding transactions on the Shanghai Stock Exchange, accounting for 0.65% of the company's total share capital. The total increase amounted to RMB 6.8535 million (excluding transaction fees). So far, Yuanjia Medical holds 15,841,600 shares of the company, accounting for 13.01% of the total issued share capital. The equity change triggers a 1% threshold, and this shareholding increase plan has not yet been fully implemented.
Hangzhou Tianmushan Pharmaceutical Co., Ltd. 2024 Annual Results Pre-Profit Announcement
ST Miao Pharmaceutical (600671.SH): Yuanjia Medical has cumulatively increased its shareholding by 0.2178%.
Gelonghui, November 25丨Special treat Muyao (600671.SH) announced that as of the date of this announcement, the implementation period of the shareholding plan has passed halfway, and Yuanjia Medical has cumulatively increased its shareholding of the company's shares by 265,200 shares, accounting for 0.2178% of the total share capital of the company, with a total increase amounting to 1.6992 million yuan. This shareholding plan has not yet been fully implemented, and Yuanjia Medical will continue to increase its shareholding of the company's shares according to the related shareholding plan within the implementation period.
Hangzhou TianMuShan Pharmaceutical Enterprise Subsidiary Renews Business License